<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01530048</url>
  </required_header>
  <id_info>
    <org_study_id>PDS290-1750</org_study_id>
    <secondary_id>2005-005538-11</secondary_id>
    <nct_id>NCT01530048</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL)</brief_title>
  <official_title>A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial, Assessing the Bioequivalence Between Insulin Aspart 100 U/mL and Insulin Aspart 200 U/mL in Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to test if there is
      bioequivalence between the insulin aspart 100 U/mL (U100) formulation and the new insulin
      aspart 200 U/mL (U200) formulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) in the interval of 0-6 hours</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax, maximum concentration</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC in the interval of 0-infinity hours</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax, time to reach Cmax</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/f, volume of distribution during terminal phase</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tÂ½, terminal half-life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCGIR, area under the glucose infusion rate value curve</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIRmax, maximum glucose infusion rate value</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tGIRmax, time to maximum glucose infusion rate value</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>U200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>U100</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin aspart</intervention_name>
    <description>A single bolus injection of 0.2 U/kg administered subcutaneously (s.c., under the skin) on two separate dosing visits with a wash-out period 2-15 days in-between</description>
    <arm_group_label>U200</arm_group_label>
    <arm_group_label>U100</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Considered to be healthy as judged from vital signs, medical history, ECG
             (electrocardiogram), laboratory values, and physical examination

          -  Body mass index between 18 and 27 kg/m^2 (both inclusive)

          -  Non-smoker

          -  Fasting blood glucose maximum 6 mmol/L

          -  HbA1c below 6.4%

        Exclusion Criteria:

          -  Pregnant or breast-feeding women

          -  Women not using acceptable methods of contraception without difficulties for at least
             three months prior to trial start (screening), including intrauterine devices, oral
             contraceptives, hormonal implants, or sterilisation

          -  Clinically significant abnormal laboratory values (as judged by the Investigator)

          -  Close relative with type 1 diabetes mellitus (father, mother, sister or brother)

          -  Intake of alcohol within the last 24 hours prior to screening and drug administration
             visits

          -  Blood donation or blood loss of more than 500 mL within the 3 last months before
             screening

          -  Strenuous exercise within 48 hours before screening as well as drug administration and
             followup

          -  Smoking during the past month before drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2012</study_first_submitted>
  <study_first_submitted_qc>February 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2012</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

